Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE - Delayed Quote USD

Novo Nordisk A/S (NVO)

Compare
58.08
-4.80
(-7.63%)
At close: April 17 at 4:00:01 PM EDT
58.83
+0.75
+(1.29%)
After hours: April 17 at 7:59:56 PM EDT
Loading Chart for NVO
  • Previous Close 62.88
  • Open 57.91
  • Bid 58.75 x 800
  • Ask 58.98 x 900
  • Day's Range 57.28 - 59.06
  • 52 Week Range 57.28 - 148.15
  • Volume 30,204,789
  • Avg. Volume 8,816,732
  • Market Cap (intraday) 282.79B
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 16.98
  • EPS (TTM) 3.42
  • Earnings Date May 7, 2025
  • Forward Dividend & Yield 1.62 (2.78%)
  • Ex-Dividend Date Mar 31, 2025
  • 1y Target Est 101.28

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com

76,302

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVO

View More

Performance Overview: NVO

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

NVO
31.16%
OMX Copenhagen 25 Index (^OMXC25)
14.74%

1-Year Return

NVO
52.43%
OMX Copenhagen 25 Index (^OMXC25)
19.44%

3-Year Return

NVO
2.80%
OMX Copenhagen 25 Index (^OMXC25)
0.00%

5-Year Return

NVO
99.92%
OMX Copenhagen 25 Index (^OMXC25)
25.76%

Compare To: NVO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVO

View More

Valuation Measures

As of 4/17/2025
  • Market Cap

    282.79B

  • Enterprise Value

    294.36B

  • Trailing P/E

    16.97

  • Forward P/E

    13.99

  • PEG Ratio (5yr expected)

    0.86

  • Price/Sales (ttm)

    5.90

  • Price/Book (mrq)

    11.88

  • Enterprise Value/Revenue

    6.70

  • Enterprise Value/EBITDA

    14.17

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    34.78%

  • Return on Assets (ttm)

    22.41%

  • Return on Equity (ttm)

    80.77%

  • Revenue (ttm)

    290.4B

  • Net Income Avi to Common (ttm)

    100.99B

  • Diluted EPS (ttm)

    3.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.31B

  • Total Debt/Equity (mrq)

    71.64%

  • Levered Free Cash Flow (ttm)

    61.99B

Research Analysis: NVO

View More

People Also Watch